New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
NCT ID NCT07514169
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of four drugs (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab) in 30 older patients (70+) newly diagnosed with large B-cell lymphoma who are too frail for standard chemo. The goal is to see if this gentler regimen can control the cancer and improve quality of life. Participants receive the drugs intravenously and orally over 12 cycles (21 days each).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab
What this could lead to
If successful, this could offer a gentler, effective treatment option for older patients with large B-cell lymphoma who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••